Is metformin a statin
Change the course of history Bibliography References can be downloaded. Thank You Notes We appreciate the hard work of the registration team at the Netherlands Comprehensive Cancer Organization in Eindhoven. In addition, we’d like to express our gratitude to the PHARMO Institute for Drug Outcomes Analysis for their diligent data collection. The European Foundation for the Study of Diabetes provided funding for this study (EFSD).
There are no conflicts of interest declared by the writers. The PHARMO Database Network for Drug Outcomes Research employs Dr MPPvH-S and RMCH. This non-profit research institute conducts studies for the government, associated healthcare agencies, and a number of pharmaceutical companies. This research, on the other hand, is not funded by a pharmaceutical firm.
The standard license to publish agreement governs the publication of this work. The work will become publicly accessible after 12 months, and the license terms will be changed to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. On the British Journal of Cancer website, there is Supplementary Material for this article. Additional details
The best “natural” pills to discuss/recommend for patients
A study that found statins, either alone or in combination with metformin, were linked to lower prostate cancer and all-cause mortality in men with high-risk prostate cancer may raise more questions about these already widely used drugs.
Dr ross walker talks about insulin resistance, diabetes
“For diabetic patients, metformin is the first-line treatment. The study’s senior author, Grace Lu-Yao, PhD, MPH, told The ASCO Post, “The majority of diabetic patients are taking metformin and then going on to take it in combination with insulin or other medications.” She added, “Diabetic patients can take statins because they are at risk for cardiovascular disease,” according to the American Diabetes Association. This is especially true for older patients, such as those in the prostate cancer report, who were 74 years old at the time of diagnosis. “That is why almost all of the men in our sample who took metformin also took statins,” she said. Dr. Lu-Yao is Associate Director of Population Science at Jefferson Health’s Sidney Kimmel Cancer Center and Vice Chair of Medical Oncology at Philadelphia’s Sidney Kimmel Medical College.
The truth about metformin | #askdave on rxmuscle.com
Metformin is the first-line treatment for Type 2 diabetes, and it is a weight-neutral medicine. However, additional unintended weight loss in the elderly may be considered a side effect of the treatment.
The Cochrane Library, PubMed, and EMBASE were all searched. We included at least 12 week-long placebo-controlled studies in which the average age of metformin-treated patients was 60 years or older and the patients’ body weight changes were registered. PROSPERO was used to register our protocol (CRD42017055287).
The meta-analysis included 6 randomized placebo-controlled studies (RCTs) (n = 1541 participants) from the 971 articles found by the quest. In the metformin-treated groups, a raw difference of -2.23 kg (95 percent CI: -2.84 –-1.62 kg) in body weight shift was observed as compared to the placebo groups (p0.001). Following metformin therapy, total cholesterol levels (-0.184 mmol/L, p0.001) and LDL cholesterol levels (-0.182 mmol/L, p0.001) also decreased.
According to the findings of a retrospective study published in Cancer Medicine, men with high-risk prostate cancer who took statins alone or in conjunction with metformin had a lower mortality rate.
In a press release, Grace Lu-Yao, PhD, associate director of population science at Sidney Kimmel Cancer Center at Jefferson Health, said, “Both metformin and statins have been correlated with longer life [among men with] prostate cancer, but no research we know of has looked at these two drugs separately because they are widely administered together.”
Around 15% of men diagnosed with prostate cancer have high-risk disease, which means they have a high risk of systemic or local recurrence, as well as a higher risk of dying from the disease. Although preclinical studies suggested that the diabetes medication metformin and cholesterol-lowering statins could slow the spread of prostate cancer, the individual and combined effects of their use in men with high-risk disease had not been quantified.